Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC)

被引：0
|
作者：
Eckardt, J
Depierre, A
Ardizzoni, A
VonPawel, J
Fields, S
机构：
[1] ST JOHNS MERCY HOSP,ST LOUIS,MO
[2] HOP ST JACQUES,F-25030 BESANCON,FRANCE
[3] ZENT KRANKENHAUS GAUTING,D-82131 GAUTING,GERMANY
[4] SMITHKLINE BEECHAM PHARMACEUT,COLLEGEVILLE,PA 19426
来源：
EUROPEAN JOURNAL OF CANCER | 1997年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1041 / 1041
页数：1
相关论文
共 50 条
  • [41] AMRUBICIN (AMR) VS TOPOTECAN AS SECOND-LINE TREATMENT OF EXTENSIVE-DISEASE SMALL CELL LUNG CANCER (SCLC) SENSITIVE TO PLATINUM-BASED FIRST-LINE CHEMOTHERAPY: A RANDOMIZED PHASE 2 TRIAL
    Jotte, R. M.
    Reynolds, C.
    Conkling, P.
    Jungnelius, U.
    Oliver, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 116 - 116
  • [42] A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC)
    Lovly, Christine Marie
    Li, Chung-I
    Hutchison, Anne Smith
    Carbone, David Paul
    Johnson, David H.
    Keedy, Vicki Leigh
    Pao, William
    Sandler, Alan
    Horn, Leora
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC)
    Venepalli, N. K.
    Hutchison, A. S.
    Carbone, D. P.
    Johnson, D. H.
    Keedy, V. L.
    Pao, W.
    Sandler, A.
    Horn, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] European Organization for Research and Treatment of Cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer
    Ardizzoni, A
    Manegold, C
    Debruyne, C
    Gaafar, R
    Buchholz, E
    Smit, EF
    Lianes, P
    ten Velde, G
    Bosquee, L
    Legrand, C
    Neumaier, C
    King, K
    Giaccone, G
    CLINICAL CANCER RESEARCH, 2003, 9 (01) : 143 - 150
  • [45] Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment
    Lambrecht, Laura
    Arnold, Paola
    Behr, Juergen
    Mertsch, Pontus
    Tufman, Amanda
    Kauffmann-Guerrero, Diego
    DIAGNOSTICS, 2024, 14 (14)
  • [46] A PHASE II STUDY OF WEEKLY GEMCITABINE-TOPOTECAN IN PRETREATED SMALL CELL LUNG CANCER (SCLC) PATIENTS (PTS)
    Domine, M.
    Gonzalez-Larriba, J. L.
    Lopez-Vilarino, J. A.
    Puente, J.
    Rubio, G.
    Alfonso, R.
    Martin-Valades, J. I.
    Rodriguez, L.
    Izarzugaza, Y.
    Lobo, F.
    ANNALS OF ONCOLOGY, 2010, 21 : 160 - 160
  • [47] A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer
    Owonikoko, Taofeek K.
    Behera, Madhusmita
    Chen, Zhengjia
    Bhimani, Chandar
    Curran, Walter J.
    Khuri, Fadlo R.
    Ramalingam, Suresh S.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (05) : 866 - 872
  • [48] A randomized phase 2 trial of amrubicin compared to topotecan as second-line treatments in extensive disease small cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy
    Jotte, R. M.
    Reynolds, C. H.
    Conkling, P.
    Oliver, J. W.
    Allen, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] Sacituzumab Govitecan as Second-Line Treatment in Patients with Extensive Stage Small Cell Lung Cancer
    Dowlati, A.
    Chiang, A. C.
    Cervantes, A.
    Babu, S.
    Hamilton, E.
    Wong, S. F.
    Tazbirkova, A.
    Sullivan, I. G.
    van Marcke, C.
    Italiano, A.
    Patel, J.
    Mekan, S.
    Wu, T.
    Waqar, S. N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S16 - S16
  • [50] NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer
    Gregorc, Vanesa
    Cavina, Raffaele
    Novello, Sivia
    Grossi, Francesco
    Lazzari, Chiara
    Capelletto, Enrica
    Genova, Carlo
    Salini, Giulia
    Lambiase, Antonio
    Santoro, Armando
    ONCOLOGIST, 2018, 23 (10): : 1133 - +
12345